KAT2B polymorphism identified for drug abuse in African Americans with regulatory links to drug abuse pathways in human prefrontal cortex.
- Authors
- Johnson, Eric O; Hancock, Dana B; Levy, Joshua L; Gaddis, Nathan C; Page, Grier P; Glasheen, Cristie; Saccone, Nancy L; Bierut, Laura J; Kral, Alex H
- Year
- 2016
- Journal
- Addiction biology
- PMID
- 26202629
- DOI
- 10.1111/adb.12286
- PMCID
- PMC4724343
Drug abuse is a common and heritable set of disorders, but the underlying genetic factors are largely unknown. We conducted genome-wide association studies of drug abuse using 7 million imputed single nucleotide polymorphisms (SNPs) and insertions/deletions in African Americans (AAs; n = 3742) and European Americans (EAs; n = 6845). Cases were drawn from the Urban Health Study of street-recruited people, who injected drugs and reported abusing opioids, cocaine, marijuana, stimulants and/or other drugs 10 or more times in the past 30 days, and were compared with population controls. Independent replication testing was conducted in 755 AAs and 1131 EAs from the Genetic Association Information Network. An intronic SNP (rs9829896) in the K(lysine) acetyltransferase 2B (KAT2B) gene was significantly associated with drug abuse in AAs (P = 4.63 × 10 ) and independently replicated in AAs (P = 0.0019). The rs9829896-C allele (frequency = 12%) had odds ratios of 0.68 and 0.53 across the AA cohorts: meta-analysis P = 3.93 × 10 . Rs9829896-C was not associated with drug abuse across the EA cohorts: frequency = 36% and meta-analysis P = 0.12. Using dorsolateral prefrontal cortex data from the BrainCloud cohort, we found that rs9829896-C was associated with reduced KAT2B expression in AAs (n = 113, P = 0.050) but not EAs (n = 110, P = 0.39). KAT2B encodes a transcriptional regulator in the cyclic adenosine monophosphate and dopamine signaling pathways, and rs9829896-C was associated with expression of genes in these pathways: reduced CREBBP expression (P = 0.011) and increased OPRM1 expression (P = 0.016), both in AAs only. Our study identified the KAT2B SNP rs9829896 as having novel and biologically plausible associations with drug abuse and gene expression in AAs but not EAs, suggesting ancestry-specific effects.
Pipeline for generating a control data set for comparison to drug abuse cases from the Urban Health Study.
Gene expression in post-mortem human prefrontal cortex samples from BrainCloud, as stratified by rs9829896 genotype. Gene expression profiles for (A) KAT2B, (B) CREBBP, and (C) OPRM1 are presented separately for 113 African Americans (AA) and 110 European Americans (denoted CAUC). Genotypes are designated as ‘1’ for the major allele homozygotes (AA), ‘2’ for heterozygotes, and ‘3’ for minor allele homozygotes (CC).
| Name | Type |
|---|---|
| 1000 Genomes AFR local | cohort |
| 1000 Genomes Project | cohort |
| AA | cohort |
| AA cohorts | cohort |
| AA-specific GWAS local | cohort |
| addiction | phenotype |
| addiction phenotypes | phenotype |
| ADH1B | gene |
| AFR | cohort |
| African | cohort |
| African American | cohort |
| alcohol | phenotype |
| alcohol abuse | phenotype |
| alcohol dependence | phenotype |
| ALDH2 | gene |
| Amphetamines/stimulants local | drug |
| Amphetamine/stimulant abuse local | phenotype |
| amphetamine/stimulants local | drug |
| Amphetamine/stimulants local | drug |
| behavioral response to cocaine local | phenotype |
| Biased genotype-phenotype associations local | phenotype |
| BiGS local | cohort |
| bipolar disorder | phenotype |
| BrainCloud | cohort |
| BrainCloud local | drug |
| BrainCloud cohort local | cohort |
| BrainCloud project local | cohort |
| C17orf58 | gene |
| cases cohort local | cohort |
| Chrna3 | gene |
| CHRNA5 | gene |
| Chrnb4 | gene |
| cigarettes | phenotype |
| cocaine | phenotype |
| COGEND | cohort |
| control data sets local | cohort |
| control population | cohort |
| controls cohort local | cohort |
| CREB1 | gene |
| CREBBP | gene |
| Cross-Disorder Group of the Psychiatric Genomics local | cohort |
| CRTC2 local | gene |
| dbGaP | cohort |
| Dependence symptoms | phenotype |
| discovery sample | cohort |
| dorsolateral prefrontal cortex | anatomy |
| Drug Abuse Case (30-day injection + ≥10 uses) local | phenotype |
| Drug Abuse Cases Cohort local | cohort |
| Drug Abuse GWAS Cohort local | cohort |
| Drug abuse phenotype local | phenotype |
| Drug Abuse Phenotype local | phenotype |
| drug abuse phenotypes local | phenotype |
| drug dependence | phenotype |
| drug rewarding effects local | phenotype |
| drugs | drug |
| drug-seeking behavior | phenotype |
| DSM criteria | phenotype |
| DSM-IV | phenotype |
| DSM-IV Drug Abuse/Dependence local | phenotype |
| DSM-IV marijuana local | phenotype |
| EA | cohort |
| EAs | cohort |
| EA-specific GWAS local | cohort |
| EUR | cohort |
| European ancestry | cohort |
| expression level local | phenotype |
| FLJ30838 local | gene |
| frontal cortex | anatomy |
| GAIN | cohort |
| GAIN AAs local | cohort |
| GAIN African Americans local | cohort |
| GAIN cohort local | cohort |
| GAIN European Americans local | cohort |
| Genetic Association Information Network (GAIN) GWAS of Schizophrenia local | cohort |
| genetic variants | cohort |
| GWAS meta-analysis (both ancestry groups) local | cohort |
| HapMap3 | cohort |
| heavy drinking | phenotype |
| heroin/opioids local | drug |
| Heroin/opioids local | drug |
| human brain | anatomy |
| illicit drugs | phenotype |
| illicit drug use | phenotype |
| Impute2 | drug |
| imputed SNP and indel genotype dosages local | variant |
| imputed SNPs | variant |
| indel | variant |
| injection local | drug |
| Injection Drug Use Phenotype local | phenotype |
| KAT2B | gene |
| KYNU local | gene |
| lower CREBBP expression local | phenotype |
| MAML1 local | gene |
| marijuana | phenotype |
| marijuana abuse | phenotype |
| marijuana dependence | phenotype |
| marijuana use disorder | phenotype |
| mood disorders | phenotype |
| multiancestry GWAS meta-analysis local | cohort |
| multi-drug abuse | phenotype |
| National Surveys on Drug Use and Health local | cohort |
| natural opioids local | drug |
| nicotine | drug |
| nicotine dependence | phenotype |
| NSDUH | cohort |
| nucleus accumbens | anatomy |
| opioid | drug |
| opioid dependence | phenotype |
| OPRM1 | cohort |
| other drug dependence | phenotype |
| other drugs | drug |
| People who inject drugs (PWID) local | cohort |
| Population Controls Cohort local | cohort |
| post-mortem dorsolateral prefrontal cortex samples local | anatomy |
| prefrontal cortex | anatomy |
| psychiatric disorders | phenotype |
| putamen | anatomy |
| PWID local | cohort |
| PWID local | phenotype |
| PWIDs local | cohort |
| Replication Study Cohort local | cohort |
| reward sensitivity | phenotype |
| rs17552189 local | variant |
| rs2381356 local | variant |
| rs8071463 local | variant |
| rs9829896 | variant |
| rs9891146 local | variant |
| rs9891146-T local | variant |
| rs9897982 local | variant |
| SAGE | cohort |
| schizophrenia | phenotype |
| Schizophrenia Working Group of the Psychiatric Genomics local | cohort |
| smoking | phenotype |
| SNP | cohort |
| stimulants | drug |
| study cohort | cohort |
| synthetic opioids local | drug |
| temperament | phenotype |
| True cases local | phenotype |
| UHS | cohort |
| UHS drug abuse cases local | cohort |
| UHS subjects local | cohort |
| United States | cohort |
No uploaded files.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Genome-wide meta-analyses of cross substance use disorders in diverse populations. | Lai D et al. | — | 2026 | → |
| Pharmacogenetic association study of cannabis use in chronic pain. | Beauchesne W et al. | — | 2026 | → |
| Pharmacogenetic association study of cannabis use in chronic pain | Beauchesne W et al. | — | 2025 | — |
| Common and distinguishing genetic factors for substance use behavior and disorder: an integrated analysis of genomic and transcriptomic studies from both human and animal studies. | Chang XW et al. | — | 2022 | → |
| GAWMerge expands GWAS sample size and diversity by combining array-based genotyping and whole-genome sequencing. | Mathur R et al. | — | 2022 | → |
| Molecular genetics of cocaine use disorders in humans. | Fernàndez-Castillo N et al. | — | 2022 | → |
| Association of Stress, Glucocorticoid Receptor, and FK506 Binding Protein Gene Polymorphisms With Internalizing Disorders Among HIV-Infected Children and Adolescents From Kampala and Masaka Districts-Uganda. | Owalla TJ et al. | — | 2021 | → |
| Different biases in meta-analyses of case-control and cohort studies: an example from genomics and precision medicine. | Palumbo SA et al. | — | 2021 | → |
| Integrating genomics and transcriptomics: Towards deciphering ADHD. | Pujol-Gualdo N et al. | — | 2021 | → |
| A case-control genome wide association study of substance use disorder (SUD) identifies novel variants on chromosome 7p14.1 in patients from the United Arab Emirates (UAE). | Alblooshi H et al. | — | 2019 | → |
| Genome-wide association meta-analysis of cocaine dependence: Shared genetics with comorbid conditions. | Cabana-Domínguez J et al. | — | 2019 | → |
| Prediction of causal genes and gene expression analysis of attention-deficit hyperactivity disorder in the different brain region, a comprehensive integrative analysis of ADHD. | Fahira A et al. | — | 2019 | → |
| Evaluation of previous substance dependence genome-wide significant findings in a Spanish sample. | Pineda-Cirera L et al. | — | 2018 | → |
| Human Genetics of Addiction: New Insights and Future Directions. | Hancock DB et al. | — | 2018 | → |
| A Review of Genome-Wide Association Studies of Stimulant and Opioid Use Disorders. | Jensen KP | — | 2016 | → |
| Genetic background and epigenetic modifications in the core of the nucleus accumbens predict addiction-like behavior in a rat model. | Flagel SB et al. | — | 2016 | → |
| Relationships between cell cycle pathway gene polymorphisms and risk of hepatocellular carcinoma. | Nan YL et al. | — | 2016 | → |